Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers

AimsTo demonstrate the efficacy of exenatide versus insulin glargine on endothelial functions and cardiovascular risk markers.MethodsThirty-four insulin and incretin-naive patients with type 2 diabetes mellitus (body mass index 25-45 kg/m2) who received metformin for at least two months were randomized to exenatide or insulin glargine treatment arms and followed-up for 26 weeks. Measurements of endothelial functions were done by ultrasonography, cardiovascular risk markers by serum enzyme-linked immunosorbent assay, and total body fat mass by bioimpedance.ResultsLevels of high sensitivity-C-reactive protein and endothelin-1 decreased (27.5% and 18.75%, respectively) in the exenatide arm. However, in the insulin glargine arm, fibrinogen, monocyte chemoattractant protein-1, leptin and endothelin-1 levels (13.4, 30.2, 47.5, and 80%, respectively) increased. Post-treatment flow mediated dilatation and endothelium independent vascular responses were significantly higher in both arms (p = 0.0001, p = 0.0001). Positive correlation was observed between the changes in body weight and endothelium-independent vasodilatation, leptin, plasminogen activator inhibitor type 1 and endothelin-1 in both arms (r = 0.376, r = 0.507, r = 0.490, r = 0.362, respectively).ConclusionsInsulin glargine improved endothelial functions, without leading to positive changes in cardiovascular risk markers. Exenatide treatment of 26 weeks resulted in reduced body weight and improvement in certain cardiovascular risk markers and endothelial functions.